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WE HAVE PREVIOUSLY DEMONSTRATED that, at least in regard to acute acid-base disturbances, the rate of HCO 3 Ϫ reabsorption (J HCO 3 ) by the S2 segment of the rabbit proximal tubule (PT) does not respond to changes in pH per se, neither intracellular nor basolateral pH (pH BL ), but instead responds appropriately to changes in baseline CO 2 ([CO 2 ] BL ) and HCO 3 Ϫ concentration ([HCO 3 Ϫ ] BL ) (35) . These results are consistent with the presence of some sort of CO 2 sensor at or near the basolateral membrane. More recently, we have extended our earlier observations by showing that the J HCO 3 response of the PT to changes in [CO 2 ] BL disappears in the presence of nanomolar levels of inhibitors that were designed to block the ErbB family of receptor tyrosine kinases (33) . In addition, we found that we can eliminate the J HCO 3 response by introduction of blockers of the AT 1 -type angiotensin II (ANG II) receptor into the lumen of rabbit PTs or by knockout of AT 1A receptor in mice (34) . This last series of results supports the well-established hypothesis (5, 19) that the PT can secrete into its lumen either ANG II or an ANG II precursor, that is, angiotensinogen or ANG I, that apical enzymes then convert to ANG II. However, it has remained unclear just what angiotensin-related species that the PT secretes.
The classic endocrine renin-angiotensin system (RAS) plays an important role in regulating cardiovascular function (7, 13, 21) . Moreover, the elements of the classic RAS are well understood: the secretion of angiotensinogen by the liver, the secretion of renin by juxtaglomerular cells in the kidney, the conversion by renin of angiotensinogen to ANG I, the presence of angiotensin-converting enzyme (ACE) on endothelial cells, the conversion by ACE of ANG I to ANG II, and the actions of ANG II on the vasculature, kidney, and adrenal cortex.
Investigators also have identified several examples of "local" or "tissue" RAS (3, 20) , operating more or less autonomously from the classic endocrine RAS and using tissue-specific mechanisms to regulate local ANG II levels, in a wide range of tissues, such as the central nervous system, heart, vasculature, and reproductive tract. Indeed, the first local system to be elucidated was the intrarenal RAS (4, 15) . The PT cell has all the components for its own RAS (4), including angiotensinogen, renin, ANG I, and brush-border ACE (8, 28) , to generate local ANG II (5, 19) . Our earlier work (34) indicates that the RAS in the PT plays at least a critical permissive role in the J HCO 3 response to alterations in [CO 2 ] BL .
In the present study, we tested the hypotheses that 1) the PT secretes not ANG II but either angiotensinogen or ANG I, and therefore 2) blocking apical ACE (i.e., preventing ANG I 3 ANG II) should be equivalent to blocking apical AT 1 receptors. We examined the effect of the ACE inhibitor lisinopril, added to either the lumen or bath (i.e., basolateral solution), on the CO 2 -induced stimulation of HCO 3 Ϫ reabsorption in renal proximal tubules. Our approach was to perfuse isolated S2 segments from the rabbit and to use out-of-equilibrium (OOE) solutions to vary [CO 2 ] BL from 0 to 20% while keeping [HCO 3 Ϫ ] BL and pH BL fixed near their physiological values. Surprisingly, we found that submicromolar levels of lisinopril had no effect on J HCO 3 when we added the drug to the lumen but reduced baseline J HCO 3 (i.e., the value when [CO 2 ] BL ϭ 5%) and eliminated the [CO 2 ] BL sensitivity of J HCO 3 when we added the drug to the bath. These results indicate that the proximal tubule secretes mainly preformed ANG II, rather than an ANG II precursor, into the tubule lumen and suggest that the lisinopril added to the bath acts by blocking the intracellular conversion of ANG I to ANG II.
METHODS
Biological preparation. "Pathogen-free" female rabbits (New Zealand White, Elite; Charles River Laboratories, Wilmington, MA) were used in the present study. The procedures were approved by the Yale Animal Care and Use Committee. In brief, our approach for obtaining and perfusing rabbit proximal tubules was similar to that originally described by Burg et al. (2) and later modified by Baum et al. (1) and also by our laboratory (18, 31) . Rabbits (1.4 -2.0 kg) were euthanized with pentobarbital sodium (40 mg), given as a single intravenous overdose. After surgically exposing and removing the left kidney, we obtained coronal sections, which we incubated in Hanks' solution (solution 1 in Table 1 ). We then microdissected slices, isolating individual midcortical S2 PT segments, each 1.5-1.7 mm long (31) . Using concentric holding, perfusion, and exchange pipettes, we cannulated the "perfusion end" of the tubule, randomly selecting (and recording the choice) either the more proximal or more distal end of the tubule. We cannulated the "collection end" of the tubule using a holding pipette. Finally, we collected samples using a calibrated collection pipette (volume Х55 nl), as summarized in Fig. 1 B in Ref. 31 .
The mean length of perfused rabbit tubules in our J HCO 3 /JV (rate of fluid reabsorption) experiments was 1.23 Ϯ 0.02 mm (n ϭ 57 tubules), and the mean luminal collection rate was 12.74 Ϯ 0.07 nl/min (n ϭ 114 collection periods). We perfused the basolateral side of the tubule (i.e., "bath") at 7 ml/min, with a solution at 37°C.
Experimental protocol and solutions. Our protocol was virtually identical to the one that we used in previous studies (32) (33) (34) (35) except that, in the present study, we added lisinopril (a gift from Merck, Rahway, NJ), a specific ACE inhibitor, to the luminal or basolateral solution.
Listed in Table 1 are the compositions of the solutions, which are identical to those used in our most recent study (34) . The luminal perfusate was always solution 2, containing dialyzed [ 3 H]methoxyinulin (PerkinElmer Life Sciences, Boston, MA) as a volume marker. During a 20-to 30-min warm-up period, solution 3 at 37°C flowed through the bath. Afterward, during the actual experiment, solution 4 (equilibrated CO 2/HCO3 Ϫ ) flowed through the bath during the first of the two collection periods. During the second of the two collection periods, solution 5 or 6 flowed through the bath. These two OOE CO2/HCO 3 Ϫ solutions had a [CO2]BL of 0 or 20%, respectively, but a "normal" [HCO 3 Ϫ ]BL (i.e., 22 mM) and pHBL (i.e., 7.40). We rapidly mixed solutions 5A and 5B to yield solution 5, and we rapidly mixed solutions 6A and 6B to yield solution 6. The osmolality was 300 Ϯ 2 mosmol/kgH2O for all solutions.
Measurement of JHCO 3 and JV. We measured J HCO 3 (pmol ⅐ min Ϫ1 ⅐ mm Ϫ1 tubule length) and JV (nl ⅐ min Ϫ1 ⅐ mm Ϫ1 ) using an approach similar to that of McKinney and Burg (16) . In aliquots of the perfusate and collected fluid, we determined total CO 2 using a WPI "NanoFlo" device (World Precision Instruments, Sarasota, FL) in combination with reagents assembled in house, as described in Ref. 33 .
As described previously (35) , the reported mean values of J HCO 3 (or JV) for the first of two collection periods (i.e., in which the bath solution contained the "control" equilibrated 5% CO 2/HCO3 Ϫ /pH 7.40) are simple averages (i.e., not normalized). The reported values for the second of two collection periods (i.e., in which bath solution contained the "experimental" OOE solution) were normalized as in our previous studies (32) (33) (34) (35) . First, we divided the J HCO 3 (or JV) value for the second collection period by the J HCO 3 (or JV) value for the first collection period in that tubule, obtaining a pair of ratios (one for J HCO 3 and one for JV). Second, we multiplied the J HCO 3 (or JV) ratio by the unnormalized meanJ HCO 3 (or JV) value obtained during the first collection period in all experiments of the same protocol (i.e., with or without luminal lisinopril).
We made statistical comparisons between historical J HCO 3 or JV control data (i.e., in the absence of any inhibitors) and corresponding new data presented in this study using a one-way ANOVA for three groups (i.e., all data for [CO 2]BL values of 0, 5, and 20%), followed by Dunnett's multiple comparison (i.e., for more than two means), using KaleidaGraph (version 4; Synergy Software). Results are means Ϯ SE, with the number of tubules (n) from which it was calculated. Concentrations are in mM except for CO2 (given in both mM and %) and albumin (g/l). Except for solution 1, all solutions were titrated to the indicated pH at 37°C. Tris ⅐ HCL and HEPES were titrated with NaOH. *Solution was used as a luminal perfusate. †Solution was used as a basolateral perfusate.
† †Out-of-equilibrium (OOE) solutions were generated by rapidly mixing their respective A and B components in 1:1 ratio. Solutions 5A, 5B, and 6B were vigorously gassed with 100% O2 to render them free of CO2. 3 and J V . In our first set of experiments, we tested our hypotheses that the PT secretes angiotensinogen and/or ANG I into the lumen and that ACE at the extracellular surface of the brush border ultimately converts ANG I to ANG II (8) . According to the product data sheet provided by Merck, the in vitro IC 50 value for lisinopril is ϳ1.2 nM. Deddish et al. (6) reported that the IC 50 value of lisinopril for human renal ACE is 0.47 nM. In our experiments, we perfused both the lumen and the bath with equilibrated 5% CO 2 /22 mM HCO 3 Ϫ solutions at pH 7.40, adding 60 nM lisinopril to the lumen in some experiments.
RESULTS

Effects of 60 and 240 nM luminal lisinopril on the basolateral CO 2 dependence of J HCO
The open bar in Fig. 1A summarizes our control (i.e., drug free) J HCO 3 data on 28 rabbit S2 PTs from the present study. The filled bar in Fig. 1A summarizes comparable J HCO 3 data, obtained on four tubules in the presence of 60 nM luminal lisinopril, which is 50-to 120-fold greater than the published in vitro IC 50 values. We stopped collecting data at 60 nM lisinopril when we observed no obvious inhibition in the presence of 5% CO 2 . The effect of 60 nM luminal lisinopril is not statistically significant.
We continued our assessment of the effect of luminal lisinopril by increasing the concentration of the drug fourfold, to 240 nM (i.e., 200-to 500-fold higher than published in vitro IC 50 values), using the same protocol as in Fig. 1 . The filled circles in Fig The above data are consistent with the following interpretations. 1) The PT secretes angiotensinogen or ANG I, but even 240 nM lisinopril is inadequate to block ACE on the luminal side of the apical membrane, the published in vitro data notwithstanding.
2) The PT secretes preformed ANG II, in which case the status of apical ACE and the sensitivity of this ACE to lisinopril are inconsequential.
Figures 1B and 2B summarize the J V data. The statistical analysis shows that none of the J V values is significantly different from the historical control at the same [CO 2 ] BL .
Effects of 60 and 240 nM basolateral lisinopril on the basolateral CO 2 dependence of J HCO 3 and J V . Our first two sets of experiments indicate that, when added to the lumen, neither 60 nM (Fig. 1) nor 240 nM lisinopril (Fig. 2) has an effect on , the computed statistical power is 96%. the basolateral CO 2 dependence of J HCO 3 and J V . In our third set of experiments, we examined the effect of basolateral lisinopril (in the absence of luminal lisinopril). The control data (Fig. 3A , open circles) are the same as in Fig. 2A . When we saw that 60 nM basolateral lisinopril (Fig. 3A , filled triangle) reduced J HCO 3 , but not quite to the "pedestal" level that we normally observe at 0% CO 2 , we stopped collecting data at this lisinopril concentration. Figure 3B summarizes the effect of 60 nM basolateral lisinopril on J V at a [CO 2 ] BL of 20%. The control data (Fig. 3B , open circles) are the same as in Fig. 2B .
Our limited experiments at 60 nM basolateral lisinopril provided an important clue that lisinopril might cross the basolateral membrane to inhibit the intracellular ACE-like activity. If this hypothesis is correct, then increasing the concentration of basolateral lisinopril ought to lead to higher intracellular levels of the drug, and thus to a greater inhibition of J HCO 3 . Therefore, in our fourth set of experiments, we followed the same protocol as above but increased the basolateral concentration of lisinopril to 240 nM. As summarized by the filled diamonds in Fig. 3A Fig. 3A) . The most straightforward explanation for these data is that lisinopril enters the PT cell across the basolateral membrane and, by blocking intracellular ACE, prevents the secretion of the preformed ANG II that is required for the stimulation of HCO 3 Ϫ reabsorption by basolateral CO 2 .
The filled diamonds in Fig. 3B summarize the J V data obtained with 240 nM basolateral lisinopril and show that the drug had no significant effect on J V at this concentration.
Effects of luminal 100 M lisinopril on the basolateral CO 2 dependence of J HCO 3 and J V . The preceding data show that whereas nanomolar levels of lisinopril, when added to the bath, substantially inhibit (filled triangle in Fig. 3A) or block (filled diamonds in Fig. 3A ) the CO 2 -dependent component of J HCO 3 , these same levels of lisinopril fail to reduce J HCO 3 when added to the lumen (Fig. 1A and Fig. 2A ). The most straightforward explanation for these results is that ACE has already converted ANG I to ANG II before the enzyme reaches the brush border and that lisinopril does not readily cross the apical membrane of PT to inhibit intracellular ACE. If this hypothesis is true, then raising the luminal lisinopril concentration to levels that others have used with enalaprilat (22) might raise the apical lisinopril influx sufficiently to inhibit intracellular ACE and thereby reduce J HCO 3 .
To test the above hypothesis, we followed the protocol of These data are consistent with the hypothesis that at extremely high luminal concentrations of lisinopril, the drug enters the PT cell at sufficiently high rates to block intracellular ACE-like activity, presumably doing so by directly entering the cell across the apical membrane or by crossing the tight junctions and then entering across the basolateral membrane.
The filled squares in Fig. 4B summarize the J V data obtained with 100 M luminal lisinopril and show that the drug had no significant effect on J V .
Effects of 10 Ϫ11 M ANG II in the presence of 240 nM basolateral lisinopril. A trivial explanation for the data in Fig.  3A is that 60 nM basolateral lisinopril, and even more so, 240 nM basolateral lisinopril, merely causes a nonspecific blockade of acid-base transport. If the inhibitory effect of lisinopril is truly limited to the blockade of ANG II production, leaving intact the ANG II receptors and the downstream signal-transduction processes and transporters, then we ought to be able to overcome the inhibitory effect of lisinopril by adding exogenous ANG II. Previous investigators (9, 10) as well as we (32) have shown that low-dose basolateral ANG II increases J HCO 3 in PTs. Therefore, with equilibrated 5% CO 2 /22 mM HCO 3 Ϫ in both the lumen and bath, we examined the effect of adding 
10
Ϫ11 M ANG II to the bath in the presence of 240 nM basolateral lisinopril.
As we have already shown in Fig. 3A , 240 nM basolateral lisinopril significantly reduces J HCO 3 (Fig. 5A, lightly shaded vs. open bar), whereas 10 Ϫ11 M ANG II in the presence of basolateral 240 nM lisinopril still raises J HCO 3 (darkly shaded bar) to virtually the same level as in previous experiments in which we added the ANG II in the absence of an ACE inhibitor (32) . Thus, even though 240 nM basolateral lisinopril blocks the tubule's J HCO 3 sensitivity to basolateral CO 2 , this drug leaves the tubule susceptible to stimulation by basolateral ANG II.
Figure 5B shows that in the presence of 240 nM basolateral lisinopril, 10 Ϫ11 M ANG II did not have a statistically significant effect on J V .
DISCUSSION
Intrarenal RAS. The renal PT cell contains all of the components necessary for a local RAS (4). For example, PT cells are positive for angiotensinogen mRNA (12), compartmentalize angiotensinogen protein in a membrane-bound compartment (11), and are positive for the protein at the brush border (23) . Moreover, cultured PT cells secrete immunoreactive angiotensinogen into the apical fluid (23) . Note, however, that the detected protein could include, or consist entirely of, remnant angiotensinogen (i.e., after cleavage of ANG I).
Renin mRNA is present in cultured rabbit PT cells, and renin activity is present in lysates from these cells (17) . In PT cells, renin protein is in granular and vesicular compartments (26) , where it colocalizes with angiotensinogen protein (11) . In addition, cultured PT cells secrete reninlike activity into the culture medium (29) .
The ANG I concentration in the PT fluid of anesthetized rats is higher than in the blood plasma (19) , consistent with the hypothesis that PT cells secrete ANG I. Using an immunodetection assay, Hunt et al. (11) obtained evidence for the secretion of ANG I by renal cortical cells, although they could not rule out the secretion of ANG II, and demonstrated that the extracellular addition of a peptidic renin inhibitor had no effect on this secretion. These last results strongly support the hypothesis that PT cells convert angiotensinogen to ANG I within a vesicular compartment in the secretory pathway (Fig. 7) .
ACE mRNA is present in PT cells (24) . Using subcellular fractionation, Ward et al. (28) demonstrated the presence of ACE activity in the PT brush border (8) . Indeed, immunocytochemistry demonstrates the presence of ACE on the brush border of proximal convoluted tubules (24) . Finally, in anesthetized rats, ANG II is present in the PT fluid at concentrations much higher than those in blood plasma (5, 19) .
Not only do the PT and certain other nephron segments have all the components necessary for a local RAS, but the intrarenal RAS can play an important functional role in modulating both vascular parameters, such as renal plasma flow and glomerular filtration rate (for reviews, see Refs. 4, 14) , and tubule parameters, including the reabsorption of Na ϩ and fluid (1, 22) as well as HCO 3 Ϫ (1, 34) . Effect of lisinopril on J HCO 3 . Our previous study (34) demonstrated that either blocking the apical AT 1 receptor with candesartan in rabbits or knocking out the AT 1A receptor in mice eliminated the PT's J HCO 3 response to changes in [CO 2 ] BL . These results confirm that the PT can somehow deliver ANG II to the PT lumen and that this luminal ANG II acts in an autocrine fashion. However, neither our earlier study nor those of others could distinguish among three possible options for luminal ANG II delivery: 1) The tubule could secrete angiotensinogen and renin into the lumen, while the vesicular membrane simultaneously delivers ACE to the brush border. The secreted renin could convert the angiotensinogen to ANG I, and the exocytosed ACE could convert the ANG I to ANG II.
2) The tubule could convert angiotensinogen to ANG I in a vesicular compartment and then secrete renin, remnant angiotensinogen, and preformed ANG I into the lumen, while the vesicular membrane simultaneously delivers ACE to the brush border. The exocytosed ACE would convert the ANG I to ANG II.
3) The tubule could convert angiotensinogen to ANG I and then convert ANG I to ANG II, all in a vesicular compartment. The PT cell then would secrete renin, remnant angiotensinogen, the NH 2 -terminal dipeptide from ANG I, and preformed ANG II into the lumen, while the vesicular membrane would simultaneously deliver ACE to the brush border.
Of course, options 2 and 3 could be more complicated if the vesicular renin could not convert all of the angiotensinogen to ANG I or if the vesicular ACE could not convert all of the ANG I to ANG II. The physiological effect of any secreted angiotensinogen would obviously depend on the rate of luminal ANG II synthesis (which would depend on the local luminal concentration of angiotensinogen, luminal renin activity, and the apical ACE activity), the linear velocity of fluid along the tubule lumen (which would carry angiotensinogen and ANG I to more distal sites), the concentration of preexisting luminal ANG II (recall that ANG II has a biphasic effect on tubule transport), and the rate of ANG II degradation, all of which would likely vary with distance along the nephron. Similar logic applies to the physiological effect of any secreted ANG I. Thus it is possible that if the PT secretes angiotensinogen or ANG I, some of the secreted material might not have a physiological action (after conversion to ANG II) until it reaches the distal nephron.
Our initial hypotheses were option 1, followed by option 2. However, if most of the luminal ANG II arises from the conversion of ANG I to ANG II by brush-border ACE, then adding lisinopril to the lumen should have markedly lowered luminal [ANG II] and thus reduced baseline J HCO 3 and eliminated the sensitivity of J HCO 3 to changes in [CO 2 ] BL . In our initial experiments, we applied 60 nM lisinopril to the lumen, a concentration that is ϳ50-to 120-fold higher than the in vitro IC 50 value. However, in four initial experiments, this concentration, which should have blocked 98 -99% of accessible ACE according to published values for the in vitro IC 50 of lisinopril, had no effect on J HCO 3 (Fig. 1A) . Moreover, when we increased luminal lisinopril concentration to 240 nM, which should have blocked 99.5-99.8% of accessible ACE, the lisinopril still had no effect on either baseline J HCO 3 or sensitivity of J HCO 3 to changes in [CO 2 ] BL from 0 to 20% at a fixed [HCO 3 Ϫ ] BL of 22 mM and a fixed pH BL of 7.4 ( Fig. 2A) . Only when we raised luminal lisinopril concentration to 100 M (Fig. 4A) , which should have blocked ϳ99.999% of accessible ACE, did we observe a substantial effect, consistent with earlier results obtained with the luminal application of enalaprilat (22) . We consider it highly unlikely that blocking 99.999% vs. 99.5-99.8% of the brush-border conversion of ANG I to ANG II should have produced an appreciable difference in luminal [ANG II], and thus a noticeable difference in J HCO 3 .
These data are consistent with two hypotheses: 1) The conversion of most ANG I to ANG II does indeed take place at the brush border, but PT ACE is unusually insensitive to lisinopril. However, the IC 50 value of 0.47 nM obtained by Deddish et al. (6) argues that renal ACE is extremely sensitive to lisinopril. 2) PT cells convert most ANG I to ANG II in a vesicular compartment and secrete preformed ANG II into the lumen. According to this latter view: a) lisinopril added to the lumen blocks brush-border ACE only after the enzyme has already converted ANG I to ANG II, b) lisinopril fails to block vesicular ACE because the inhibitor cannot efficiently cross the apical membrane, and c) the inhibitor can efficiently cross the basolateral membrane.
If hypothesis 1 were true and PT ACE had an unusually low sensitivity to lisinopril, then we should not have observed substantial inhibition of J HCO 3 until the basolateral lisinopril concentration had reached extremely high levels. However, we found that applying as little as 60 nM lisinopril in the bath reduced J HCO 3 at a [CO 2 ] BL of 20% from ϳ89 to ϳ57 pmol⅐min Ϫ1 ⅐mm
Ϫ1
(filled triangle in Fig. 3A ), which represents an approximately two-thirds inhibition of the flux above the pedestal level of ϳ32 pmol⅐min Ϫ1 ⅐mm
. Raising basolateral lisinopril to 240 nM reduced J HCO 3 to the pedestal level at [CO 2 ] BL levels from 0% to 20% (filled diamonds in Fig. 3A) . Thus, consistent with the IC 50 value of Deddish et al. (6) , our data indicate that PT ACE is reasonably sensitive to the drug and therefore that hypothesis 1 must be incorrect. We conclude that the PT secretes mainly intact ANG II (i.e., hypothesis 2).
To rule out the possibility that lisinopril nonspecifically blocks PT acid-base transport, we asked whether, in the presence of 240 nM basolateral lisinopril, 10 Ϫ11 M basolateral ANG II could still raise J HCO 3 . Indeed, Fig. 5A demonstrates that PT can still respond to basolateral ANG II even though it cannot respond to basolateral CO 2 . Thus we propose that the J HCO 3 response to basolateral CO 2 requires the luminal secretion of preformed ANG II.
Effect of lisinopril on the flux of "other" solutes. In an earlier study (34) , we found that the acute blockade of apical angiotensin AT receptors by saralasin, or of AT 1 receptors by candesartan, had no significant effect on J V . In the present study, we found that basolateral lisinopril had no significant effect on J V at a concentration of either 60 nM (filled triangle in Fig. 3B ) or 240 nM (filled diamonds in Fig. 3B ). Luminal lisinopril also did not have an effect on J V , at either 60 nM (Fig. 1B) or 240 nM (filled circles in Fig. 2B ). Only 100 M luminal lisinopril had a statistically significant effect on J V , and then only at 20% CO 2 .
Because basolateral lisinopril substantially reduced J HCO 3 at 20% CO 2 (Fig. 3A) but did not have a significant effect J V (Fig.  3B) , the drug must have substantially increased the reabsorption rate for solutes other than NaHCO 3 (J Other ). In other words, reciprocal effects of lisinopril on J HCO 3 and J Other stabilized fluid reabsorption at 20% CO 2 .
J Other . In Fig. 6A , the open circles and solid lines, the control J HCO 3 , summarize both the historical and present control data (n ϭ 152) from Figs. 2A, 3A, and 4A. In Fig. 6C , we have similarly replotted the J HCO 3 data for basolateral 240 nM lisinopril (from Fig. 3A ) and for luminal 100 M lisinopril (from Fig. 4A ). In Fig. 6 , A and C, we also have plotted values for J Other , which we computed (as described in the Fig. 6 legend) for each of these three sets of J HCO 3 and J V data. In the absence of lisinopril (Fig. 6A) , J Other and J HCO 3 had a reciprocal relationship, which explains the relative stability of J V in Figs. 2B, 3B, and 4B. Luminal lisinopril (100 M) caused J Other at 20% CO 2 (Fig. 6C ) to rise significantly above the corresponding control values (Fig. 6A) . The effects of 240 nM basolateral and 100 M luminal lisinopril at 5% CO 2 , as well as 240 nM basolateral lisinopril at 20% CO 2 , on J Other did not reach statistical significance.
Concentration of NaHCO 3 and other solutes in the reabsorbate. In Fig. 6B, we show the values that we computed for concentrations of NaHCO 3 ([NaHCO 3 ]) and "other" solutes ([Other]) in the PT reabsorbate under control conditions. In Fig. 6D Conclusions. Our data indicate that the isolated perfused rabbit S2 PT secretes predominantly preformed ANG II, as opposed to either angiotensinogen or ANG I. We propose that the conversion of angiotensinogen to ANG I, as well as the subsequent conversion of ANG I to ANG II, takes place in an intracellular vesicle (Fig. 7) . We suggest that the PT also secretes remnant angiotensinogen (which would presumably cross-react with angiotensinogen antibodies) and the NH 2 -terminal dipeptide cleaved from ANG I, or breakdown products thereof. Fig. 7 . Model of the endogenous secretion of ANG II. We suggest that inside intracellular vesicles, the proximal tubule (PT) converts the majority of angiotensinogen (Agt) to ANG I and then to ANG II. In terms of angiotensinrelated products, the fusion of these vesicles with the PT apical membrane would result in the secretion mainly of preformed ANG II and remnant angiotensinogen (rAgt). The PT would also secrete renin and deliver angiotensin-converting enzyme (ACE) to the brush border. Escaping vesicular peptidase activity may be small amounts of Agt and ANG I, which could then be cleaved by renin and ACE in the lumen of the PT or later nephron segments. The lumen of the ACE-containing vesicle is presumably readily accessible to basolateral but not to luminal lisinopril. At extremely high levels (e.g., 100 M), luminal lisinopril could reach ACE-containing vesicles by either leaking across the apical membrane or passing first through tight junctions and then leaking across the basolateral membrane. Basolateral membranes tend to have higher permeabilities than do apical membranes (reviewed in Ref. 30) , specific examples being the permeabilities to NH 3 (25, 27) and CO 2 (27) .
In retrospect, it is perhaps not surprising that the conversion from angiotensinogen to ANG II should take place almost entirely within an intracellular vesicle, inasmuch as the contents of the vesicle would have protracted exposure, before the vesicle fuses with the apical membrane, to renin and ACE.
